Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.75 |
| ▸ | CDK2 | P24941 | 5/20 | 0.75 |
| ▸ | PRKACA | P17612 | 4/20 | 0.75 |
| ▸ | CDK7 | P50613 | 4/20 | 0.75 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.75 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.75 |
| ▸ | PAK4 | O96013 | 3/20 | 0.75 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.75 |
| ▸ | PRKCG | P05129 | 3/20 | 0.75 |
| ▸ | PIM1 | P11309 | 3/20 | 0.75 |
| ▸ | PHKG2 | P15735 | 3/20 | 0.75 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.75 |
| ▸ | AKT2 | P31751 | 3/20 | 0.75 |
| ▸ | FLT3 | P36888 | 3/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.75 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.75 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.75 |
| ▸ | GSK3A | P49840 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386101 | 1.00 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL2191613 | 1.00 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL2191602 | 1.00 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL29388655 | 1.00 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL6857775 | 1.00 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL6855324 | 0.96 | AKT1 (0.70) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL6853580 | 0.94 | AKT1 (0.77) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL6853479 | 0.94 | AKT1 (0.67) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL7168788 | 0.92 | AKT1 (0.75) | AKT1CDK2PRKACACDK7DAPK3 | |
| SCHEMBL6835405 | 0.92 | AKT1 (0.65) | AKT1CDK2PRKACACDK7DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-115116561-A | Construction method and application of drug-target protein-schizophrenia interaction network | 南方医科大学南方医院 | 2022-09-27 | — | — | CN | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2022165216-A1 | METHODS FOR INCREASING VIRAL TRANSDUCTION OF CELLS | CARPENTER MARGARET CLARK (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-11319376-B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | REMD BIOTHERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | AKT1 18/4885CDK2 317/4885PRKACA 773/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AKT1 153/4885CDK2 47/4885PRKACA 415/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | AKT1 6/4885CDK2 24/4885PRKACA 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.